Land: Malta
Språk: engelsk
Kilde: Medicines Authority
CARBIDOPA, ENTACAPONE, LEVODOPA
Actavis Group PTC ehf Revkjavikurvegi 76-78, 220 Hafnarfjordur, Iceland
N04BA03
CARBIDOPA 43.75 mg ENTACAPONE 200 mg LEVODOPA 175 mg
FILM-COATED TABLET
CARBIDOPA 43.75 mg ENTACAPONE 200 mg LEVODOPA 175 mg
POM
ANTI-PARKINSON DRUGS
Withdrawn
2014-08-25
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER _ _ SASTRAVI 50 MG/12.5 MG/200 MG FILM-COATED TABLETS SASTRAVI 75 MG/18.75 MG/200 MG FILM-COATED TABLETS SASTRAVI 100 MG/25 MG/200 MG FILM-COATED TABLETS SASTRAVI 125 MG/31.25 MG/200 MG FILM-COATED TABLETS SASTRAVI 150 MG/37.5 MG/200 MG FILM-COATED TABLETS SASTRAVI 175 MG/43.75 MG/200 MG FILM-COATED TABLETS SASTRAVI 200 MG/50 MG/200 MG FILM-COATED TABLETS levodopa/carbidopa/entacapone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. _ _ WHAT IS IN THIS LEAFLET 1. What Sastravi is and what it is used for 2. What you need to know before you take Sastravi 3. How to take Sastravi 4. Possible side effects 5. How to store Sastravi 6. Contents of the pack and other information 1. WHAT SASTRAVI IS AND WHAT IT IS USED FOR Sastravi contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Sastravi is used for the treatment of Parkinson’s disease. Parkinson’s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson’s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SASTRAVI _ _ Les hele dokumentet
Page 1 of 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Sastravi 50 mg/12.5 mg/200 mg film-coated tablets Sastravi 75 mg/18.75 mg/200 mg film-coated tablets Sastravi 100 mg/25 mg/200 mg film-coated tablets Sastravi 125 mg/31.25 mg/200 mg film-coated tablets Sastravi 150 mg/37.5 mg/200 mg film-coated tablets Sastravi 175 mg/43.75 mg/200 mg film-coated tablets Sastravi 200 mg/50 mg/200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 50 mg of levodopa, 12.5 mg of carbidopa (as monohydrate) and 200 mg of entacapone. Each film-coated tablet contains 75 mg of levodopa, 18.75 mg of carbidopa (as monohydrate) and 200 mg of entacapone. Each film-coated tablet contains 100 mg of levodopa, 25 mg of carbidopa (as monohydrate)and 200 mg of entacapone. Each film-coated tablet contains 125 mg of levodopa, 31.25 mg of carbidopa (as monohydrate)and 200 mg of entacapone. Each film-coated tablet contains 150 mg of levodopa, 37.5 mg of carbidopa (as monohydrate)and 200 mg of entacapone. Each film-coated tablet contains 175 mg of levodopa, 43.75 mg of carbidopa (as monohydrate)and 200 mg of entacapone. Each film-coated tablet contains 200 mg of levodopa, 50 mg of carbidopa (as monohydrate)and 200 mg of entacapone. _ _ Excipient with known effect: Each film-coated tablet contains 0.48 mg lecithin (soya) (E322). Each film-coated tablet contains 0.54 mg lecithin (soya) (E322). Each film-coated tablet contains 0.60 mg lecithin (soya) (E322). Each film-coated tablet contains 0.66 mg lecithin (soya) (E322). Each film-coated tablet contains 0.72 mg lecithin (soya) (E322). Each film-coated tablet contains 0.78 mg lecithin (soya) (E322). Each film-coated tablet contains 0.83 mg lecithin ( Les hele dokumentet